Globalisation of industry-sponsored clinical trials for breast, lung and colon cancer research: trends, threats and opportunities

• DOI: 10.1136/bmjonc-2023-000101
• Publication Date: 2023-09-30T10:55:13Z
• Authors: Anil Babu Payedim...; Samir Mouhssine; Saleh Aljadeeah; Gianluca Gaidano; Raffaella Ravinetto
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282; Original Research

Objective Breast, lung, colon cancers are the ‘big killers’ in oncology. Access to innovative treatments lags behind low-income and middle-income countries. We investigated geographic distribution of industry-sponsored trials; whether results were reported clinical trial registries. Methods analysis conducted a search ClinicalTrials.gov by: (i) study type: interventional; (ii) condition: breast, cancer; (iii) phases: I–IV; (iv) funder: industry. Trials registered as 30 June 2018 extracted; for completed trials, second extraction was performed on September 2022. Results included 4177 trials. Phase I–IV trials involving only high-income countries 3254/4177 (77.9%), while 923/4177 (22.1%) at least one site (MICs). Most phase III (416/688; 60.5%) involved MICs, including lower MICs (6/416, 1.4%), upper (225/416, 54.1%) (185/416, 44.5%). IV 45/89 (50.6%) cases. I II smaller proportions (72/950, 7.6% 390/2450, 15.9%, respectively). No run (LICs). Among 430 out 1854 (23.2%) MICs. had not been entered registry 63.4% (1176/1854) overall 49.5% (213/430) Conclusion lung increasingly delocalised likely unable get access medicines. Furthermore, LICs hosting any Measures needed ensure benefit-sharing countries; improve transparency stimulate research addressing needs LICs.